serologic response evaluation

PreclinicalBiologic

GGruppo Italiano Malattie EMatologiche dell'Adulto

serologic response evaluation is one of 51 biologic programs targeting Efficacy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EfficacyNot yet recruiting

EfficacyPreclinical

Not yet recruiting

Competition

Competitive Landscape

139 competitors in Efficacy

#DrugCompanyPhaseTrials

Rayos

RRoxane Laboratories

Phase 3

5 2

Paraplatin

AAvyxa

Phase 3

4 3

Lesinurad

EEsperion Therapeutics, Inc.

Phase 3

2 4

Insulin 320

Novo Nordisk

Phase 3

5 5

Endothelin Receptor Antagonist

RRadboud University Medical Center

Phase 3

1 6

Sepofarsen

PProQR Therapeutics

Phase 3

1 7

Veracept

SSebela Women's Health Inc.

Phase 3

1 8

Cetaphil

GGalderma R&D

Phase 3

1 9

Aralen

Sanofi

Preclinical

2 10

Primaquine

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

N/ANot yet recruiting

Efficacy

NCT06364033

Clinical

Trials by Indication[1]

Efficacy1 trial

Biological and Clinical Efficacy of Shingrix in Patients With CLL

Not yet recruiting·GGruppo Italiano Malattie EMatologiche dell'Adulto·N/A·NCT06364033·312 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for serologic response evaluation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — serologic response evaluation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for serologic response evaluation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gruppo Italiano Malattie EMatologiche dell'Adulto company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: GGruppo Italiano Malattie EMatologiche dell'Adulto

serologic response evaluation

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Efficacy1 trial

References

Drug Info

Quick Facts

Related News